TORONTO, Jan. 29, 2021 (World NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global chief in specialized, study-pushed pharmaceutical-excellent cannabis extraction, distillation and derivative goods, is delighted to announce Greg Hunter will be part of MediPharm Labs as Chief Fiscal Officer (CFO), powerful February 8, 2021.

Greg Hunter provides in excess of 20 decades of expertise as a small business govt holding a variety of senior finance and management roles throughout multiple industries including health care distribution, telecommunications, prescribed drugs, biotechnology, health care gadget and purchaser packaged goods. Greg also delivers a track history and deep experience in cash administration, audit, compliance, tax, treasury, ERP, production, contract management and pricing system.

“As MediPharm proceeds to concentration on accelerating the progress and execution of our world pharmaceutical, overall health and wellness small business, Greg’s qualifications in expanding significant pharmaceutical functions combined with a observe document in strategic money allocation and price tag management is a solid addition to our Corporation,” explained Keith Strachan, President and Interim CEO, MediPharm Labs. “As we glimpse to seize new growth options and broaden our item choices, his addition will guarantee that we are very well positioned to execute on our programs and provide successful development in the upcoming.”

Most lately, Greg was Main Monetary Officer of Medical Pharmacies Team Minimal, a foremost pharmacy and health-related devices producer and distributor in Canada. Previously in the pharmaceuticals marketplace, Greg held numerous senior management roles with Baxter Worldwide Inc. which includes serving as CFO of Baxter’s Canadian subsidiary. Greg also previously held several senior operational and finance roles at Janssen-Ortho Inc., a Johnson and Johnson business.

Keith Strachan added, “I would also like to thank Olga Utkutug for her many contributions and leadership as Interim CFO. We look forward to her continued assistance as a essential member of our finance team.”

Greg retains an MBA from McMaster College, an Honors B.Sc. in Microbiology and Immunology from College of Western Ontario and is a Chartered Expert Accountant.

In connection with Greg’s appointment as CFO, the Firm granted 600,000 stock options to him with an exercising value established at the close of company on January 28, 2021. Each grant has a 5-calendar year term expiring January 28, 2026, and vests in 5 equivalent instalments, the very first of which vests right away with the 4 other instalments vesting on the dates which are six, twelve, eighteen and twenty-four months from the grant day. The stock options are issue to any required regulatory approvals.

About MediPharm Labs Corp.

Established in 2015, MediPharm Labs specializes in the output of purified, pharmaceutical quality hashish oil and concentrates and superior derivative merchandise utilizing a Good Production Practices certified facility with ISO common built cleanse rooms. MediPharm Labs has invested in an specialist, research-driven crew, condition-of-the-artwork technological innovation, downstream purification methodologies and reason-crafted amenities with 5 key extraction strains for delivery of pure, reliable and precision -dosed hashish products and solutions for its clients. As a result of its wholesale and white label platforms, they formulate, consumer-check, procedure, package deal and distribute hashish extracts and innovative cannabinoid-centered items to domestic and global markets. As a global chief, MediPharm Labs has done business exports to Australia and has absolutely commercialized its wholly-owned Australian extraction facility. MediPharm Labs Australia was established in 2017.

CAUTIONARY Notice Pertaining to Ahead-Searching Information and facts:

This news launch contains “forward-seeking information” and “forward-searching statements” (collectively, “forward-wanting statements”) inside of the that means of the relevant Canadian securities legislation. All statements, other than statements of historical truth, are ahead-seeking statements and are based on anticipations, estimates and projections as at the day of this news launch. Any assertion that involves discussions with regard to predictions, anticipations, beliefs, strategies, projections, targets, assumptions, future functions or performance (typically but not often working with phrases this sort of as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variants of these types of words and phrases and phrases or stating that selected actions, activities or final results “may” or “could”, “would”, “might” or “will” be taken to come about or be achieved) are not statements of historic simple fact and may be forward-seeking statements. In this information release, ahead-wanting statements relate to, amid other things, statements pertaining to: accelerating the progress and execution of the Company’s world pharmaceutical, health and fitness and wellness organization new progress prospects expanded product offerings and executing on designs and delivering rewarding development in the potential. Forward-looking statements are essentially centered upon a number of estimates and assumptions that, whilst regarded fair, are subject to recognised and unfamiliar dangers, uncertainties, and other aspects which may perhaps result in the actual success and potential functions to differ materially from all those expressed or implied by these forward-looking statements. This sort of variables include, but are not confined to: normal business enterprise, financial, competitive, political and social uncertainties the lack of ability of MediPharm Labs to get hold of ample funding the delay or failure to obtain regulatory approvals and other things talked over in MediPharm Labs’ filings, offered on the SEDAR site at www.sedar.com. There can be no assurance that this sort of statements will confirm to be exact, as actual success and foreseeable future activities could differ materially from those people anticipated in these statements. Accordingly, audience need to not position undue reliance on the forward-wanting statements and facts contained in this news launch. Other than as needed by law, MediPharm Labs assumes no obligation to update the forward-hunting statements of beliefs, views, projections, or other elements, should really they transform.

For even more information, make sure you contact: Laura Lepore, VP, Investor Relations Telephone: 705-719-7425 ext 1525 Email: [email protected] Web page: www.medipharmlabs.com